1. Introduction {#sec1-ijms-16-26077}
===============

Gallbladder cancer (GBC) is infrequent, however, it is very aggressive, and also the most common biliary tract cancer worldwide with marked geographical, racial and gender-specific orientations \[[@B1-ijms-16-26077],[@B2-ijms-16-26077]\]. The etiology of GBC is multifactorial with gallstone and chronic inflammation as the root of disease \[[@B3-ijms-16-26077],[@B4-ijms-16-26077]\]. Due to the absence of specific symptoms and late presentation, more than 90% of GBC patients are diagnosed at an advanced stage with little treatment alternatives \[[@B5-ijms-16-26077]\]. Owing to unsatisfactory treatment options, the five-year survival rate is less than 5% and neither chemotherapy nor radiotherapy have been shown to improve the overall quality of life \[[@B6-ijms-16-26077]\]. Further, despite recent advancements, the molecular basis of GBC is poorly understood and it still remains a diagnostic and therapeutic challenge for clinicians \[[@B7-ijms-16-26077]\]. Thus, there is always a need to develop novel biomarker for its early diagnosis, and to enhance our understanding of inter-individual variability in vulnerability of GBC.

Previously, we have examined the role of various candidate gene variations in GBC patients from North India. These variants are part of genes involved in various signaling pathways, including apoptosis, cell survival, cell--cell interaction, estrogen metabolism, *etc.* \[[@B8-ijms-16-26077],[@B9-ijms-16-26077],[@B10-ijms-16-26077],[@B11-ijms-16-26077],[@B12-ijms-16-26077]\]. However, being low penetrance genetic variations, their individual contribution towards GBC is very small and single SNPs cannot exactly account for GBC susceptibility. Further, carcinogenesis is a highly intricate process and polygenic in nature involving multiple gene variations of mild consequence \[[@B13-ijms-16-26077]\]. In addition, gene--gene and gene--environment interactions are believed to be major players in the pathogenesis of GBC and can modulate individual's susceptibility to cancer \[[@B14-ijms-16-26077]\]. Hence, we have extended our earlier work by simultaneously exploring 14 polymorphisms in nine genes (*DR4*: A\>C (rs20576), G\>A (rs6557634); *FAS*-1377G\>A (rs2234767); *FASL*-844T\>C (rs763110); *DCC*:C \>G (rs2229080), A\>G (rs4078288), C\>T (rs7504990), A\>G (rs714); *PSCA*:C\>T (rs2294008), G\>A (rs2978974); *ADRA2A*-1291C\>G (rs1801253); *ADRB1* 1165C\>G (rs1800544); *ADRB3* 190T\>C (rs4994); *CYP17* T\>C (rs2486758)) by using Multifactor-Dimensionality Reduction (MDR) method and classification and regression trees (CRT) to determine possible higher order gene--gene interactions and accomplish a comprehensive appraisal of GBC risk. These are a non-parametric, genetic model-free methodologies \[[@B15-ijms-16-26077]\] having advantage to identify association in studies having small sample sizes and low penetrance of candidate SNPs as compared to previous traditional methods such as logistic regression \[[@B16-ijms-16-26077],[@B17-ijms-16-26077]\].

2. Results {#sec2-ijms-16-26077}
==========

The demographic profile of GBC patients and controls are displayed in [Table 1](#ijms-16-26077-t001){ref-type="table"}. The mean age of 400 GBC cases and 246 controls were 52.65 ± 10.45 and 47.75 ± 10.65 years, respectively. Most of the GBC patients (\~95%) were in stage III and stage IV of cancer.

ijms-16-26077-t001_Table 1

###### 

Characteristic of the Study Subjects.

  Variables           Cases N (%)     Controls N (%)
  ------------------- --------------- ----------------
  Whole Subjects      400 (100)       246 (100)
  Female              278 (69.5)      163 (66.3)
  Male                122 (30.5)      83 (33.7)
  Age ± SD            52.65 ± 10.45   47.75 ± 10.65
  Stages                              
  0, I                None            NA
  II                  21 (5.25)       
  III                 199 (49.75)     
  IV                  180 (45.0)      
  Gallstone present   200 (50.0)      None
  Gallstone absent    200 (50.0)      246 (100)
  Tobacco                             
  No                  273 (68.9)      NA
  Yes                 123 (31.1)      

NA: not available.

2.1. Single Locus Analysis {#sec2dot1-ijms-16-26077}
--------------------------

[Table 2](#ijms-16-26077-t002){ref-type="table"} represents the association of all the studied SNPs with GBC risk. The heterozygous genotypes of *DR4* (rs20576, rs6557634), and variant genotype of *DCC* rs4078288 was found to confer significantly increased risk of GBC (adjusted OR \> 1; *p* \< 0.05). Further, both hetero- and variant-genotypes of *DCC* rs714 and ADRB3 rs4994 were associated with the increased susceptibility of GBC, whereas genotype containing at least one variant allele of *DCC* rs2229080 was found to confer protection against GBC risk.

ijms-16-26077-t002_Table 2

###### 

Single locus analysis of SNPs investigated.

  Pathway                       Gene        SNP         MAF~controls~       MAF~cases~          OR~het~ ^a^           OR~hom~ ^a^
  ----------------------------- ----------- ----------- ------------------- ------------------- --------------------- --------------------
  Death receptor                *Dr4*       rs20576     8                   14                  1.82 (1.18--2.83)     3.27 (0.93--11.51)
  rs6557634                     27          33          1.61 (1.06--2.44)   2.05 (0.90--4.70)                         
  *FAS*                         rs763110    39          41                  0.94 (0.66--1.33)   1.26 (0.78--2.02)     
  *FASL*                        rs2234767   20          22                  0.99 (0.71--1.38)   1.66 (0.70--4.12)     
  Tumor suppressor              *DCC*       rs714       37                  45                  1.84 (1.29--2.63)     1.72 (1.08--2.74)
  rs2229080                     32          24          0.64 (0.46--0.89)   0.32 (0.15--0.68)                         
  rs7504990                     32          31          1.01 (0.72--1.40)   0.92 (0.51--1.65)                         
  rs4078288                     34          39          0.98 (0.69--1.39)   1.58 (1.01--2.49)                         
  Prostate stem cell antigen    *PSCA*      rs2978974   32                  30                  0.91 (0.65--1.27)     0.86 (0.50--1.48)
  rs2294008                     42          46          1.4 (0.97--2.02)    1.25 (0.77--2.04)                         
  Adrenergic pathway            *ADRa2a*    rs1800544   45                  49                  1.35 (0.92--1.97)     1.41 (0.87--2.29)
  *ADRB3*                       rs4994      10          21                  2.58 (1.76--3.78)   10.61 (1.38--81.92)   
  *ADRB1*                       rs1801253   22          25                  1.32 (0.95--1.84)   1.12 (0.46--2.78)     
  Estrogen metabolism pathway   *CYP17*     rs2486758   26                  27                  1.04 (0.74--1.45)     1.11 (0.59--2.09)

Significant values are denoted as bold. ^a^ Adjusted for age and gender in logistic regression model; OR~het~: odds ratio of heterozygote *vs.* common homozygote genotypes; OR~hom~: odds ratio of homozygote *vs.* common homozygote genotypes, MAF: Minor allele frequency.

2.2. Multifactor Dimensionality Reduction (MDR) {#sec2dot2-ijms-16-26077}
-----------------------------------------------

Our MDR analysis demonstrated *ADRB3*~rs4994~ polymorphism (testing accuracy = 0.6003, CVC = 10/10, *p* \< 0.0001) as the one-factor model for envisaging the GBC risk. *DCC*~rs2229080~, *ADRB3*~rs4994~ constitutes the two-factor model with testing accuracy of 0.5658 but CVC = 6/10 (*p* \< 0.0001). The three-factor model, comprising *DCC*~rs714~, DCC~rs2229080~, and *ADRB3*~rs4994~ SNPs had the improved testing accuracy of 0.5913 and the CVC of 9/10 (*p* ≤ 0.0001). Likewise, *DCC*~rs714~, *DCC*~rs2229080~, *PSCA*~rs2978974~, and *ADRB3*~rs4994~ polymorphisms represents the four-factor interaction model, having a testing accuracy of 0.5353 and CVC = 3/10 with *p* \< 0.0001 ([Table 3](#ijms-16-26077-t003){ref-type="table"}).

ijms-16-26077-t003_Table 3

###### 

Multifactor dimensionality reduction (MDR) analysis showing association of high-order interactions with GBC.

  No. of Risk Factors   Best Interaction Model                                               Testing Accuracy   ^\#^ CVC   *X*² (*p*-Value)          OR (95% CI)
  --------------------- -------------------------------------------------------------------- ------------------ ---------- ------------------------- -------------------------
  1                     *ADRB3*~rs4994~                                                      0.6003             10/10      28.5717 (*p* \< 0.0001)   2.7507 (1.8841--4.0158)
  2                     *DCC*~rs2229080~, *ADRB3*~rs4994~                                    0.5658             6/10       32.5889 (*p* \< 0.0001)   2.6238 (1.8762--3.6693)
  3                     *DCC*~rs714~, *DCC*~rs2229080~, *ADRB3*~rs4994~                      0.5913             9/10       44.324 (*p* \< 0.0001)    3.0155 (2.1684--4.1935)
  4                     *DCC*~rs714~, *DCC*~rs2229080~, *PSCA*~rs2978974~, *ADRB3*~rs4994~   0.5353             3/10       68.7203 (*p* \< 0.0001)   4.0443 (2.8834--5.6726)

^\#^ The model with maximum testing accuracy and maximum CVC cross was considered as the best model; CVC: cross-validation consistency.

2.3. Classification and Regression Tree Analysis (CRT) {#sec2dot3-ijms-16-26077}
------------------------------------------------------

[Figure 1](#ijms-16-26077-f001){ref-type="fig"} depict the results of CRT analysis, containing all the studied SNPs. The tree comprised of total eleven nodes and six terminal nodes (node that has no child nodes) with *ADRB3*~rs4994~ polymorphism lying at the top of tree signifying it as the main contributing factor for GBC. Subjects with *ADRB3*~rs4994~ (W), *DCC*~rs2229080~ (H + V) and *ADRB1*~rs1801253~ (W) genotypes (Node 1) having the lowest case rate (36.94%) was taken as reference.

[Table 4](#ijms-16-26077-t004){ref-type="table"} summarizes the risk associated with all the terminal nodes compared with Node 1 (*ADRB3*~rs4994~ (W) + *DCC*~rs2229080~ (H + V) +*ADRB1*~rs1801253~ (W). Subjects having the *ADRB3*~rs4994~ (W) + *DCC*~rs2229080~ (W) + *DCC*~rs714~ (H + V) and *ADRB3*~rs4994~ (W) + *DCC*~rs2229080~ (H + V) + *ADRB1*~rs1801253~ (H + V) + *Cyp17*~rs2486758~ (H) genotypes were found to have a significantly increased GBC susceptibility (adjusted OR = 3.7; *p* = 0.0003 and OR = 3.7; *p* = 0.0001). Importantly, all the terminal nodes were comprised of *ADRB3* rs4994 and *DCC*~rs2229080~ polymorphism ([Table 4](#ijms-16-26077-t004){ref-type="table"}).
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###### 

Risk estimate based on Classification and Regression Tree Analysis (CRT) terminal nodes.

  Nodes    Genotype of Individuals in Each Node                                                                        Case   Control   Total   Case Rate (%)   *p*-Value   OR (95% CI) ^a^
  -------- ----------------------------------------------------------------------------------------------------------- ------ --------- ------- --------------- ----------- -------------------
  Node 1   *ADRB3*~rs4994~ (W) + *DCC* ~rs2229080~ (H + V) + *ADRB1*~rs1801253~ (W)                                    41     70        111     36.94           --          Reference
  Node 2   *ADRB3*~rs4994~ (W) + *DCC* ~rs2229080~ (H + V) + *ADRB1*~rs1801253~ (H + V) + *Cyp17*~rs2486758~ (W + V)   26     31        57      45.61           0.2836      1.43 (0.74--2.75)
  Node 3   *ADRB3*~rs4994~ (W) + *DCC*~rs2229080~ (W) + *DCC*~rs714~ (W)                                               29     30        59      49.15           0.1290      1.65 (0.87--3.14)
  Node 4   *ADRB3*~rs4994~ (W) + *DCC* ~rs2229080~ (W) + *DCC*~rs714~ (H + V)                                          112    52        164     68.29           0.0003      3.66 (2.21--6.12)
  Node 5   *ADRB3*~rs4994~ (W) + *DCC*~rs2229080~ (H + V) + *ADRB*1~rs1801253~ (H + V) + *Cyp17*~rs2486758~ (H)        37     17        54      68.52           0.0001      3.69 (1.86--7.50)

Case rate: Percentage of cancer patients among all individuals in each node (case/(case + control) × 100); ^a^ Adjusted for age and gender.

![Classification and regression tree model for selected 14 SNPs and GBC risk. Terminal nodes at the end. W: Wild type genotype; V: Variant genotype; H: heterozygous.](ijms-16-26077-g001){#ijms-16-26077-f001}

2.4. In-Silico Analysis {#sec2dot4-ijms-16-26077}
-----------------------

The *in-silico* analyses of all the studied SNPs are shown in [Table 5](#ijms-16-26077-t005){ref-type="table"}. MDR and CRT analysis demonstrated *ADRB3*~rs4994~ is the key causative factor in gallbladder carcinogenesis. Our *in-silico* analysis also showed this SNP to alter protein coding, splicing and transcriptional regulation. *DCC*~rs2229080~ polymorphism was also shown to change the protein coding and splicing regulation. *DCC*~rs714~ and *PSCA*~rs2978974~ are intronic SNPs with unknown function.

ijms-16-26077-t005_Table 5

###### 

Bioinformatic Analysis.

  SNPs                         Result of F-SNP/FAST SNP                                                                                
  ---------------------------- ------------------------------------------------ ---------------------------------------- ------------- -------------------
  *DR4*~rs20576~               0                                                Protein coding                           Ensemble      Nonsynnymous
  Polyphen                     Possible damaging                                                                                       
  *DR4*~rs6557634~             0.284                                            Protein coding                           Ensembl       Nonsynonymous
  Polyphen                     Probably damaging                                                                                       
  Splicing regulation          ESE finder                                       Changed                                                
  ESR Search                   Changed                                                                                                 
  *FASL*~rs763110~             0.434                                            Protein coding                           Ensembl       Frameshift-coding
  Transcriptional regulation   TF-Search                                        Changed                                                
  Ensembl-TR                   Regulatory region                                                                                       
  *FAS*~rs2234767~             0                                                Protein coding                           Ensembl       Nonsynnymous
  *DCC*~rs2229080~             0.616                                            Protein coding                           Polyphen      Probably damaging
  SNPeffect                    Deleterious                                                                                             
  LS-SNP                       Deleterious                                                                                             
                               Missense (non-conservative) Medium--high (3,4)                                                          
  Splicing regulation          ESE finder                                       Changed                                                
  ESR Search                   Changed                                                                                                 
  PESX                         Changed                                                                                                 
  *DCC*~rs4078288~             NA                                               Intronic enhancer Very low--low (1--2)                 
  *DCC*~rs7504990~             NA                                               Intronic with no known function                        
  *DCC*~rs714~                 NA                                               Intronic with no known function                        
  *Cyp17*~rs2486758~           0.176                                            Transcriptional regulation               TFSearch      Changed
  *ADRA2A*~rs1800544~          0.065                                            Transcriptional regulation               Golden path   Exit
  *ADRB3*~rs4994~              0.551                                            Protein coding                           Ensembl       Nonsynonymous
  SIFT                         Damaging                                                                                                
  SNPeffect                    Deleterious                                                                                             
  Splicing regulation          ESE finder                                       Changed                                                
  ESR Search                   Changed                                                                                                 
  PESX                         Changed                                                                                                 
  Transcriptional regulation   Golden path                                      Exit                                                   
  *ADRB1*~rs1800544~           0.774                                            Protein coding                           Ensembl       Nonsynonymous
  *CYP17*~rs2486758~           0.176                                            Transcriptional regulation               TFsearch      Changed

3. Discussion {#sec3-ijms-16-26077}
=============

Recent advancement in molecular biology has suggested extensive interactions amongst various genes or risk alleles (in which effect of single gene variation is influenced by other genetic variation *i.e.*, gene--gene interaction) as the key factor modulating the disease susceptibility. Hence, in this study, we aimed to investigate the synergistic effect of various gene variations to modulate GBC susceptibility instead of their individual effect, by using MDR and CRT. MDR improves the identification of multilocus genotype combinations (higher order gene--gene interactions) predicting the disease vulnerability for common, complex and multifactorial diseases \[[@B15-ijms-16-26077]\]. CRT analysis, which is based on recursive partitioning the data space and fitting a simple prediction model within each partition, is a powerful technique with significant potential and clinical utility \[[@B18-ijms-16-26077]\]. It categorizes the study subjects according to various risk levels on the basis of the various gene polymorphisms \[[@B19-ijms-16-26077]\]. Both MDR and CRT are widely used in large-scale association studies because of their capability to overcome sample size limitations and the curse of dimensionality as compared to case-control studies using logistic regression \[[@B16-ijms-16-26077],[@B17-ijms-16-26077]\].

Our single locus analysis showed *ARDB3*~rs4994~ as the important factor enhancing the GBC risk. The MDR analysis also showed *ADRB3*~rs4994~ alone as the best candidate with highest testing accuracy and CVC. Further, the three-factor interaction model consisting of *DCC*~rs714~, *DCC*~rs2229080~, *ADRB3*~rs4994~ constitutes the second best SNPs model with testing accuracy of 0.5913 and CVC = 9/10 (*p* \< 0.001). The result of CRT analysis further affirmed *ADRB3*~rs4994~ as the major risk factor for GBC advancement. In addition, it corroborated MDR result and showed a complex interaction amongst *ADRB3*~rs4994~, *DCC*~rs2229080~, *DCC*~rs714~ as well as *Cyp17*~rs2486758~ attributing increased susceptibility to GBC. These finding suggested some correlation among these genes or proteins.

*ADRB3*, a member of class of G-protein-coupled receptor family, is abundantly distributed in adipose tissue and regulate lipolysis and thermogenesis \[[@B20-ijms-16-26077]\]. In addition, it has been localized to vascular and nonvascular smooth muscle of human gastrointestinal tract, as well as in gallbladder regulating the blood flow and motility in gastrointestinal tract and gallbladder \[[@B21-ijms-16-26077],[@B22-ijms-16-26077]\]. *ADRB3* rs4994 is a missense variation substituting tryptophan with arginine at codon 64. This SNP has been shown to influence fat accumulation and been implicated in the etiology of obesity that may serve as the predisposing factor for GBC \[[@B23-ijms-16-26077],[@B24-ijms-16-26077]\]. It was also shown to alter the susceptibility to colon cancer risk in obese subjects \[[@B25-ijms-16-26077]\]. Moreover, it has been established to increase the risk of gallstone disease, (a precancerous lesion for GBC), suggesting it as a gene marker for increased risk for gallstone \[[@B26-ijms-16-26077],[@B27-ijms-16-26077]\]. In our previous study, we showed that *ADRB3*~rs4994~ conferred increased risk of GBC both by gallstone-dependent and -independent mechanisms \[[@B10-ijms-16-26077]\]. Here, our multi-analytical approaches further confirmed the association of this SNP, either alone or in combination, with GBC risk. On the contrary, a recent study failed to show the association of this SNP with pancreatic cancer \[[@B28-ijms-16-26077]\] may be due to different pathology underlying different organs.

*DCC* (netrin-1), originally discover in colorectal cancer, is characterized as a candidate tumor suppressor gene that encodes the netrin 1 receptor, a member of the immunoglobulin superfamily of cell adhesion molecules \[[@B29-ijms-16-26077]\]. When *DCC* is present and bound to netrin-1 receptor, it induces cell proliferation and migration, while in the absence of netrin-1, an intracellular domain of *DCC* is cleaved by a caspase inducing apoptosis in a caspase-9-dependent pathway \[[@B30-ijms-16-26077]\]. In various human cancers, it has been shown to be frequently silenced or inactivated due to loss of heterozygosity at chromosome 18q21 region or epigenetic silencing \[[@B29-ijms-16-26077],[@B31-ijms-16-26077]\]. Loss of *DCC* gene expression was shown to be an independent prognostic factor in AML \[[@B32-ijms-16-26077]\], colorectal \[[@B33-ijms-16-26077]\] and gastric cancer \[[@B34-ijms-16-26077],[@B35-ijms-16-26077]\] patients. Several studies have demonstrated significant association of *DCC* polymorphism with colorectal, esophageal, and gastric cancer risk \[[@B36-ijms-16-26077],[@B37-ijms-16-26077],[@B38-ijms-16-26077],[@B39-ijms-16-26077]\]. The deletions at 18q21 loci (containing *DCC* gene) is an important step in the progression of GBC \[[@B40-ijms-16-26077]\]. A genome-wide association study (GWAS) also suggested *DCC* as a candidate gene conferring GBC predisposition in a Japanese population \[[@B41-ijms-16-26077]\]. In our previous work, we found no effect of GWAS reported SNPs on GBC risk. On the contrary, we showed significant association of *DCC* rs714 and rs2229080 with GBC risk \[[@B12-ijms-16-26077]\]. The rs714 has been shown to be associated with loss of heterozygosity (LOH) and decreased expression of *DCC* in various cancers \[[@B42-ijms-16-26077],[@B43-ijms-16-26077]\]. Further, rs2229080, a missense variation replacing Arg to Gly at DCC codon 201, was reported to increase the risk of colorectal cancer \[[@B44-ijms-16-26077]\] and neuroblastoma \[[@B45-ijms-16-26077]\]. Moreover, this SNP was suggested to be a target of LOH and associated with loss of *DCC* protein expression indicating that the codon 201 polymorphism may interfere with the *DCC* transcription or transition \[[@B46-ijms-16-26077]\].

*PSCA*, originally identified as a prostate cell surface specific marker, was also established to be overexpressed in several other human cancers and suggested to play a role in carcinogenesis by regulating the cell proliferation, adhesion, migration and survival \[[@B47-ijms-16-26077]\]. High expression of *PSCA* is significantly associated with adverse prognostic features and cancer severity, including; differentiation, invasion, metastasis and decreased overall survival \[[@B48-ijms-16-26077],[@B49-ijms-16-26077]\]. The expression and function of *PSCA* are tissue specific, *i.e.*, it acts like tumor suppressor gene (TSG) in some organ while as oncogene (OG) in others. In GBC, it was reported to be downregulated and act like TSG by modulating immunological characteristics of GBC cells \[[@B50-ijms-16-26077],[@B51-ijms-16-26077],[@B52-ijms-16-26077]\]. However, a recent study has shown *PSCA* overexpression in GBC that is associated with invasive potential and prognosis of GBC \[[@B49-ijms-16-26077]\]. Further, several GWAS and case control studies have demonstrated association of *PSCA* gene polymorphisms rs2294008 and rs2976392 with various cancers, though some controversies also existed \[[@B48-ijms-16-26077],[@B53-ijms-16-26077],[@B54-ijms-16-26077],[@B55-ijms-16-26077],[@B56-ijms-16-26077]\]. The *PSCA*~rs2294008~, located in exon 1, was found to affect the transcriptional activity \[[@B57-ijms-16-26077],[@B58-ijms-16-26077]\] and the missense allele of rs2294008 was shown to attenuate antitumor activities of *PSCA* in GBC and consequently it was suggested to be a potential risk for GBC development \[[@B51-ijms-16-26077]\]. The rs2976392G\>A positioned in intron 2 is in strong linkage disequilibrium with rs2294008C\>T, and its function is unclear till yet \[[@B59-ijms-16-26077]\]. In our previous study, we failed to find the association of *PSCA* polymorphism with GBC risk, but on gender stratification, Trs2294008-Grs2978974 haplotype was found to confer higher risk of GBC in females (FDR Pcorr = 0.021), while Trs2294008-Ars2978974 haplotype is associated with significantly decreased risk in males (FDR Pcorr = 0.013) suggesting gender specific effect of *PSCA* haplotypes on GBC susceptibility \[[@B11-ijms-16-26077]\]. Here, we found this SNP to increase GBC risk only in combination with *DCC* and *ADRB3* SNPs, though the CVC is low (3/10, *p* \< 0.0001).

Our *in-silico* investigation of *ADRB3*~rs4994~ and *DCC*~rs2229080~ showed alteration in protein coding, splicing regulation and transcriptional regulation. *CYP17*~rs2486758~ was also found to alter transcriptional regulation. Other associated SNPs (*DCC*~rs714~, *PSCA*~rs2978974~) are intronic, hence our *in silico* study did not show any effect of these SNPs. Though, intronic SNPs are reported to be important player in splicing regulation and may affect other SNP lying in linkage disequilibrium.

Smoking/tobacco usage may be an important issue affecting disease susceptibility. However, we did consider smoking data due to non-reliability of collecting such information from controls. In earlier studies, we had therefore carried out case only analysis for modulation of genetic susceptibility by tobacco usage. However, in the present study, tobacco related analysis has not been done due to limited data. Here, we carried out only MDR and CART analysis for higher order gene--gene analysis.

4. Materials and Methods {#sec4-ijms-16-26077}
========================

4.1. Ethics Statement and Study Population {#sec4dot1-ijms-16-26077}
------------------------------------------

The present study was approved by the ethical committee of Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS). (Approval number: IEC code- 2012-170-EMP-66, approval date: 10.01.2013) Written informed consent was collected from all participants involved in the study.

A total of 646 subjects, including 400 GBC patients and 246 healthy control subjects of North Indian Ethnicity were recruited in this study from the department of Surgical Oncology, KGMU and Department of Surgical Gastroenterology SGPGIMS, Lucknow. The inclusion--exclusion criteria for cases and controls, and staging of cancer were same as previously reported in our studies \[[@B8-ijms-16-26077],[@B9-ijms-16-26077],[@B10-ijms-16-26077],[@B11-ijms-16-26077],[@B12-ijms-16-26077]\]. In general, controls were frequency-matched to cancer cases for age, gender, and ethnicity, and were free from any history of malignancy as well as gallstones. For GBC cases, only confirmed subject (by FNAC; fine needle aspirated cell cytology or histopathology) were included in the study, while those already receiving chemotherapy were excluded.

4.2. Selected SNPs and Genotyping {#sec4dot2-ijms-16-26077}
---------------------------------

In the present study, we have included *DR4*:A\>C (rs20576), G\>A (rs6557634); *FAS*-1377G\>A (rs2234767); *FASL*-844T\>C (rs763110); *DCC*:C\>G (rs2229080), A\>G (rs4078288), C\>T (rs7504990), A\>G (rs714); *PSCA*:C\>T (rs2294008), G\>A (rs2978974); *ADRA2A*-1291C\>G (rs1801253); *ADRB1* 1165C\>G (rs1800544); *ADRB3* 190T\>C (rs4994); and *CYP17* T\>C (rs2486758) SNPs.

Salting out method was used to isolate genomic DNA from 5 mL peripheral blood leukocytes \[[@B60-ijms-16-26077]\]. The genotyping was performed by the PCR restriction fragment length polymorphism and TaqMan^®^ allelic discrimination assays (Applied Biosystems 7500 Fast Real-Time PCR (Thermo Fisher Scientific, Walthan, MA, USA)) method, as described previously \[[@B8-ijms-16-26077],[@B9-ijms-16-26077],[@B10-ijms-16-26077],[@B11-ijms-16-26077],[@B12-ijms-16-26077]\]. PCR mix without DNA sample was taken as negative control and the 10% of random samples were sequenced to confirm the results consistency.

5. Statistical Analysis {#sec5-ijms-16-26077}
=======================

5.1. Single Locus Analysis {#sec5dot1-ijms-16-26077}
--------------------------

Mean with standard deviation (SD) and absolute value were used for continuous and categorical measures, respectively. The frequency distributions of SNPs genotype between cases and controls were compared by using the chi-square analysis or two-sided Fisher's exact test. Unconditional multivariate logistic regression (LR) was used to assess the odds ratios (ORs) and 95% confidence intervals (CIs) to estimate the risk of gallbladder cancer with the polymorphisms. The ORs were adjusted for age and gender. All statistical analyses were performed using SPSS software version 16.0 (SPSS, Chicago, IL, USA) and a *p*-value of less than 0.05 was considered a statistically significant.

5.2. Multifactor Dimensionality Reduction (MDR) {#sec5dot2-ijms-16-26077}
-----------------------------------------------

The MDR analysis was carried out by onine MDR software version 2.0 \[[@B61-ijms-16-26077]\] producing several genotype interaction models. Amongst them, the genotype combination having the highest testing accuracy and the cross-validation consistency (CVC) is taken as the best interaction model \[[@B62-ijms-16-26077]\]. The combined effect of the variables was calculated using LR analysis and a *p*-value less than 0.05 was considered to be statistically significant.

5.3. Classification and Regression Tree Analysis (CRT) {#sec5dot3-ijms-16-26077}
------------------------------------------------------

The SPSS software (version 16.0) was used to accomplish the CRT analysis producing a decision tree. In CRT analysis, starting with the core node comprising of the total sample, each node is divided into two child nodes repetitively by recursive partitioning \[[@B19-ijms-16-26077]\], thus creating a tree like structure. The risk of all genotypes sets was estimated by considering the node with low case rate was as the reference to calculate the ORs and 95% CIs.

5.4. In-Silico Analysis and Functional Prediction of SNPs {#sec5dot4-ijms-16-26077}
---------------------------------------------------------

Various online prediction tools such as; FASTSNP, F-SNP \[[@B63-ijms-16-26077],[@B64-ijms-16-26077],[@B65-ijms-16-26077],[@B66-ijms-16-26077]\] were used to predict the functional effects of all the studied SNPs.

6. Conclusions {#sec6-ijms-16-26077}
==============

In conclusion, we found *ADRB3* as the main SNPs associated with increased GBC susceptibility. In addition, we showed a complex interaction amongst *ADRB3, DCC, PSCA* and *CYP17* increasing GBC risk. Further, our results allow more precise definition of subjects with high or low risk for GBC. Viewing the functional consequence of these SNPs in cancer initiation and progression, it is of great importance to further look into the underlying mechanism of carcinogenesis at gene levels and their interactive pathway. Future studies exploring the panels of the risk allele for GBC susceptibility in a larger sample size may have important implications in GBC management.
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